Evotec SE
Evotec SE is a globally recognized drug discovery and development company that operates as a specialized outsourcing partner (CRO) for pharmaceutical and biotechnology firms. Evotec has established itself as a leader in providing comprehensive, integrated services that span the entire value chain from target identification to preclinical candidate nomination. The company’s core offering in Drug Discovery Services is built upon proprietary technology platforms, notably in high-throughput screening (HTS) and target validation, which utilize advanced cell-based assays and molecular techniques. By leveraging its global network and expertise, Evotec helps partners accelerate their pipelines, particularly in complex areas like oncology, neuroscience, and metabolic diseases. Their business model emphasizes deep scientific partnership and open innovation, granting them access to novel targets and supporting the efficient translation of biological insights into drug candidates.\\Charles River Laboratories International is a premier global Contract Research Organization (CRO) that provides essential preclinical and clinical services to the pharmaceutical, biotechnology, and medical device industries. A major cornerstone of their Drug Discovery Services segment is the provision of in vitro and in vivo pre-clinical research models, which are critical for validating drug targets and assessing the safety and efficacy of novel compounds. They offer integrated discovery solutions, ranging from assay development and high-throughput screening (HTS) to lead identification and optimization. Charles River has continually expanded its technology portfolio, including label-free HTS solutions, to optimize early-stage research. By serving as a seamless extension of their clients’ R\&D teams, Charles River helps accelerate the timeline from discovery to development, supporting the creation of novel targeted therapies for unmet medical needs across various therapeutic areas.\\WuXi AppTec is a global pharmaceutical and medical device R\&D and manufacturing services company, acting as a critical Contract Research Organization (CRO) in the drug discovery landscape. It provides an integrated, end-to-end open-access platform that covers chemistry, biology, and testing services, designed to help researchers create, identify, and support preclinical candidates. The company’s comprehensive Drug Discovery Services include an integrated chemistry and biology research platform that efficiently moves a project from initial hit identification through to preclinical candidate nomination. WuXi AppTec supports a diverse range of partners, from small biotech firms to major pharmaceutical corporations, by offering access to diverse chemical libraries and deep drug discovery expertise. Its strategic partnerships, such as the joint drug discovery center with AstraZeneca, solidify its role as a global enabler of innovative therapies for cancer and other complex diseases.\\Curia Global, Inc. (formerly Albany Molecular Research Inc. or AMRI) is a leading Contract Research, Development, and Manufacturing Organization (CRDMO) that offers comprehensive Drug Discovery Services. Curia specializes in providing flexible, integrated solutions that encompass the entire discovery spectrum, from initial target validation and hit identification to lead optimization and preclinical development. Their core competencies include advanced medicinal chemistry services and process development, which are crucial for synthesizing and refining novel therapeutic compounds. The company employs a strategy of aligning its flexible models with the evolving regulatory and technological needs of the pharmaceutical and biotech industries. By supporting diverse drug development pipelines with an integrated approach, Curia assists its partners in overcoming complex scientific challenges and accelerating the journey of drug candidates toward the clinic.\\Recursion Pharmaceuticals is an innovative technology company leading the charge in AI-driven drug discovery and development. The company leverages its proprietary platform, the Recursion OS, which combines one of the world’s largest fit-for-purpose biological and chemical datasets with intelligent machine learning models. The platform’s foundation involves taking images of cells to train artificial intelligence to understand the cellular disruptions driving disease, thereby revolutionizing the process of finding new targets and designing optimized molecules. Recursion’s Drug Discovery Services are focused on reducing the high failure rate of traditional R\&D by rapidly identifying potential first-in-class and best-in-class treatments for aggressive cancers and rare diseases. Through partnerships with industry giants like Bayer, Roche, and Merck, Recursion is positioning generative AI as a core technology for the future of pharmaceutical development.\\Crown Bioscience, a Contract Research Organization (CRO), is a globally recognized specialist in preclinical and translational Drug Discovery Services, with a focused expertise in oncology and immuno-oncology. The company provides essential services to biotech and pharmaceutical companies, helping to remove guesswork from their research and development processes through the use of clinically relevant in vitro and in vivo models. Crown Bioscience’s innovative solutions include exploring 3D bone marrow models and advancing ADC (Antibody-Drug Conjugate) research. By offering platforms like its extensive Cancer Model Database and CrownLink, the company enables partners to progress their IO (Immuno-Oncology) molecules and discover translational biomarkers. Their continued expansion, including new model development centers and CLIA certification to enhance clinical trial support, reinforces their pivotal role in advancing cancer drug discovery and development globally.\\F. Hoffmann-La Roche Ltd (Roche) is a global leader in pharmaceuticals and diagnostics, with its Drug Discovery Services driven by a fundamental commitment to personalized medicine and advanced molecular science. While Roche primarily focuses on developing its own pipeline, its massive investments and innovations in computational biology, genomics, and advanced molecular discovery platforms serve as foundational Drug Discovery Services that benefit the broader ecosystem. The company excels at high-throughput screening and data-driven research to streamline drug target identification and validation, particularly for complex diseases. Its sophisticated diagnostic capabilities enhance drug discovery by facilitating early identification of promising therapeutic candidates and advancing biomarker discovery and precision therapies. Roche’s strategic use of advanced internal platforms drives breakthroughs, ensuring it remains a central force in the global landscape of therapeutic innovation.\\Bristol-Myers Squibb Company (BMS) is a leading global biopharmaceutical company that actively engages in advanced drug discovery across small molecules and biologics, with a core focus on high-burden diseases like oncology, immunology, and cardiovascular disease. Its Drug Discovery Services are characterized by leveraging massive internal data-driven research and advanced screening capabilities to address critical unmet medical needs. BMS maintains a relentless focus on innovation through its extensive R\&D pipeline and strategic global collaborations that accelerate translational research. The company’s continuous commitment to pioneering biotechnology and developing next-generation therapeutic candidates places it among the most influential players in defining the standards and direction of modern drug discovery, particularly in the rapid translation of research into clinical applications.\\Pharmaron is a fully integrated Contract Research Organization (CRO) that provides comprehensive Drug Discovery Services to life sciences clients worldwide. The company’s offering is designed to support the entire R\&D process from initial idea to regulatory submission. Specifically within drug discovery, Pharmaron provides a wide array of specialized services, including various aspects of chemistry (analytical, synthetic, medicinal, and computational), biosciences (in vitro biology, in vivo pharmacology, and DMPK), and integrated drug discovery programs. These programs allow clients to move seamlessly from hit identification to preclinical candidate nomination. With strong capabilities in safety assessment and bioanalysis, Pharmaron delivers reliable and reproducible data, serving as an essential technological and operational partner that helps accelerate the pace and reduce the risk of complex drug development projects.\\Sygnature Discovery is an independent, integrated drug discovery and preclinical services Contract Research Organization (CRO). The company focuses on providing high-quality, fully-integrated drug discovery programs to pharmaceutical and biotechnology clients globally. Sygnature Discovery’s services span from target validation and hit identification through to the selection of a preclinical candidate. Their core competencies include medicinal chemistry, *in vitro* biosciences, and computational chemistry, complemented by strong expertise in protein crystallography and other preclinical services. By undertaking multi-year contracts with major pharmaceutical companies, Sygnature Discovery demonstrates its role as a trusted partner that expands its laboratory capacity to meet growing demand and successfully moves early-stage drug candidates forward in the discovery pipeline.\
Latest Market Research Report on Drug Discovery Services Download PDF Brochure Now
